Briefly, IL-6 increases the expression of CXCR7 in ESCC cells via STAT3/NF-κB signaling, ultimately fostering their chemoresistant phenotype of ESCC cells upon treatment with cisplatin both in vitro and in subcutaneous xenografts. This evidence concerns the gene STAT3 and esophageal squamous cell carcinoma.